Amyloid Polyneuropathy Type I — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for amyloid polyneuropathy type i. 5 active patents protecting 2 drugs from 1+ originators. First major cliff: 2026. Daily refresh.

2
Approved drugs
5
Active US patents
53/100
Avg vulnerability
$1.4B
Annual revenue covered

Originators in Amyloid Polyneuropathy Type I

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Foldrx Pharms 5 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating amyloid polyneuropathy type i. Each bar = one year. Y-axis scaled to peak year (4 patents).

4
26
1
35

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Vyndaqel
tafamidis
 Foldrx Pharms 3 55 $1.4B 2026-12-19
Vyndaqel
Tafamidis Meglumine
 Foldrx Pharms 2 51 — 2026-12-19

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
7214696 Vyndaqel method of use 80 2026-12-19
7214696 Vyndaqel method of use 80 2026-12-19
9770441 Vyndaqel method of use 62 2035-08-31
7214695 Vyndaqel composition of matter 22 2026-12-19
7214695 Vyndaqel composition of matter 22 2026-12-19

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
7214695 Vyndaqel composition of matter 22 2026-12-19
7214695 Vyndaqel composition of matter 22 2026-12-19
9770441 Vyndaqel method of use 62 2035-08-31
7214696 Vyndaqel method of use 80 2026-12-19
7214696 Vyndaqel method of use 80 2026-12-19

Related